What you should know:
– Curved biosciencesWhole-Body Intelligence™ company, today announced that it has raised $40 million in Series A financing led by Luma Groupwith the participation of First Spark companies, Techas Capital, civilization enterprises, LifeX Companiesand others.
– The funding will be used to accelerate the clinical validation and commercialization of its platform for monitoring chronic diseases.
Molecular model for chronic diseases
Curve Biosciences is addressing the rising costs and increasing prevalence of chronic diseases, saying improvements in patient monitoring are necessary to realize the full positive impact of modern advances such as GLP-1.
The company has developed Whole-Body Atlas™, which is described as the world’s largest collection of manually curated tissue samples characterized by organs and disease states. Returning to this biological truth at the tissue level, Curve is creating Whole-Body Blood Tests™.
These tests, powered by the company’s Whole-Body Intelligence platform, anticipate chronic diseases, guide treatment decisions and align stakeholders, including patients, insurers, pharmaceutical companies and physicians.
“To raise the bar for chronic disease monitoring, we are now introducing the first-ever whole-body intelligence platform with AI models trained on our Whole-Body Atlas and powered by our whole-body blood tests,” said Ritish Patnaik, PhD, CEO and co-founder of Curve Biosciences.
Executive leadership and clinical action capacity
The company has assembled a highly experienced executive team with deep experience in developing advanced blood tests and precision medicine solutions:
- Ritish Patnaik, PhD, CEO: Former business developer at Genentech, specializing in artificial intelligence, data engineering and precision testing.
- Nathan Hunkapiller, PhD, Chief Scientific Officer: Previously Head of R&D at Natera and GRAIL, where he led the development of advanced blood tests for oncology and prenatal screening.
- Alice Chen, PhD, Chief Operating Officer: Former head of product and program management at GRAIL, where she led strategy for a blood test for early detection of multiple cancers.
- Chuba Oyolu, PhD, Chief Technology Officer: Founding Scientist and Senior Site Director at Counsyl, with experience scaling advanced blood testing.
- Prof. Shan Wang, PhD, Chief Innovation Officer: Professor Leland T. Edwards at Stanford University, contributing more than 300 publications and more than 70 patents.
